Enhanced killing of primary ovarian cancer by retargeting autologous cytokine-induced killer cells with bispecific antibodies: A preclinical study

Clinical Cancer Research

Volumn 12, Issue 6, 2006, Pages 1859-1867

  Chan, John K ^a   Hamilton, Chad A ^a   Cheung, Michael K ^a   Karimi, Mobin ^a   Baker, Jeanette ^a   Gall, Jonathan M ^b   Schulz, Stephan ^a   Thorne, Steve H ^a   Teng, Nelson N ^a   Contag, Christopher H ^a   Lum, Lawrence G ^b   Negrin, Robert S ^a,c  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ROGER WILLIAMS MEDICAL CENTER   (United States)

^c Roger Williams Medical Center ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPECIFIC ANTIBODY; BLOCKING ANTIBODY; CA 125 ANTIGEN; CD3 ANTIGEN; CD56 ANTIGEN; CYTOKINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; NATURAL KILLER CELL RECEPTOR NKG2D;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOLUMINESCENCE; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CELL ACTIVITY; CELL INFILTRATION; CELL KILLING; CELL TRANSFER; CHROMIUM 51 RELEASE; CLINICAL ARTICLE; CONJUGATION; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXICITY; DRUG TARGETING; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; IMAGING SYSTEM; IMMUNOTHERAPY; IN VIVO STUDY; KILLER CELL; MOUSE; NONHUMAN; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCID MOUSE; TUMOR GROWTH; TUMOR REGRESSION; TUMOR VOLUME; XENOGRAFT;

ANIMALS; ANTIBODIES, BISPECIFIC; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; HUMANS; IMMUNOTHERAPY, ADOPTIVE; KILLER CELLS, NATURAL; LUCIFERASES; MICE; MICE, SCID; MICROSCOPY, FLUORESCENCE; OVARIAN NEOPLASMS; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 33645690747     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-2019     Document Type: Article

References (42)

1. Brinton LA, Lancey JV, Sherman ME. Epidemiology of gynecologic cancers. In: Hoskins WJ, Perez CA, Young DC, et al., editors. Principles and practice of gynecologic oncology. 4th ed. Philadelphia: Lippincott Williams and Wilkins; 2005. p. 9-13.
2. DiSaia PJ, Creasman WT. Epithelial ovarian cancer. In: DiSaia PJ, Creasman WT, editors. Clinical gynecologic oncology. 5th ed. St. Louis: Mosby; 2002. p. 289-350.
3. Omura GA, Brady MF, Homesley HD, et al. Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience. J Clin Oncol 1991;9:1138-50.
4. Ozols RF. Recurrent ovarian cancer: evidence-based treatment. J Clin Oncol 2002;20:1161-3.
5. Lafreniere R, Rosenberg SA. Successful immunotherapy of murine experimental hepatic metastases with lymphokine-activated killer cells and recombinant interleukin 2. Cancer Res 1985;45:3735-41.
6. Rosenberg SA, Lotze MT Muul LM, et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 1985;313:1485-92.
7. Rosenberg SA, Packard BS, Aebersold PM, et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med 1988;319:1676-80.
8. Zhang L, Conejo-Garcia JR, Katsaros D, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003;348:203-13.
9. Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004;10:942-9.
10. Leemhuis T, Wells S, Scheffold C, Edinger M, Negrin RS. A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma. Biol Blood Marrow Transplant 2005;11:181-7.
11. Takayama T, Sekine T, Makuuchi M, et al. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet 2000;356:802-7.
12. + natural killer T cells redirected with bispecific antibody F(ab′)(2)HER2xCD3. Cancer Res 2002;62:5785-91.
13. Bookman MA, Darcy KM, Clarke-Pearson D, Boothby RA, Horowitz IR. Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group. J Clin Oncol 2003;21:283-90.
14. Camilleri-Broet S, Hardy-Bessard AC, LeTourneau A, et al. HER-2 overexpression is an independent marker of poor prognosis of advanced primary ovarian carcinoma: a multicenter study of the GINECO group. Ann Oncol 2004;15:104-12.
15. Alvarez RD, To A, Boots LR, et al. CA125 as a serum marker for poor prognosis in ovarian malignancies. Gynecol Oncol 1987;26:284-9.
16. Jin Y, Zhang H, Tsao SW, et al. Cytogenetic and molecular genetic characterization of immortalized human ovarian surface epithelial cell lines: consistent loss of chromosome 13 and amplification of chromosome 20. Gynecol Oncol 2004;92:183-91.
17. + tumors. J Hematother Stem Cell Res 2001;10:247-60.
18. Carter P, Presta L, Gorman CM, et al. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci U S A 1992;89:4285-9.
19. Rodrigues ML, Shalaby MR, Werther W, Presta L, Carter P. Engineering a humanized bispecific F(ab′)2 fragment for improved binding to T cells. Int J Cancer Suppl 1992;7:45-50.
20. Shalaby MR, Shepard HM, Presta L, et al. Development of humanized bispecific antibodies reactive with cytotoxic lymphocytes and tumor cells overexpressing the HER2 protooncogene. J Exp Med 1992;175:217-25.
21. Hoyle C, Bangs CD, Chang P, et al. Expansion of Philadelphia chromosome-negative CD3(+)CD56(+) cytotoxic cells from chronic myeloid leukemia patients: in vitro and in vivo efficacy in severe combined immunodeficiency disease mice. Blood 1998;92:3318-27.
22. + regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med 2003;9:1144-50.
23. + killer cells. Blood 1995;86:3493-9.
24. Kutten WH, Miller DS, Mathis JM. Immunologic characterization of tumor markers in human ovarian cancer cell lines. J Soc Gynecol Investig 1996;3:216-22.
25. Santin AD, Ioli GR, Hiserodt JC, et al. Development and characterization of an IL-4-secreting human ovarian carcinoma cell line. Gynecol Oncol 1995;58:230-9.
26. Fuchtner C, Emma DA, Manetta A, et al. Characterization of a human ovarian carcinoma cell line: UCI 101. Gynecol Oncol 1993;48:203-9.
27. Beilhack A, Schulz S, Baker J, et al. In vivo analyses of early events in acute graft-versus-host disease reveal sequential infiltration of T-cell subsets. Blood 2005;106:1113-22.
28. + T cells. Blood 2004;103:3065-72.
29. Schmidt-Wolf IG, Finke S, Trojaneck B, et al. Phase I clinical study applying autologous immunological effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma. Br J Cancer 1999;81:1009-16.
30. Lum LG, Rathore R, Cummings F, et al. Phase I/II study of treatment of stage IV breast cancer with OKT3 x trastuzumab-armed activated T cells. Clin Breast Cancer 2003;4:212-7.
31. Menendez JA, Vellon L, Mehmi I, et al. Inhibition of fatty acid synthase (FAS) suppresses HER2/neu (erbB-2) oncogene overexpression in cancer cells. Proc Natl Acad Sci U S A 2004;101:10715-20.
32. Groh V, Wu J, Yee C, Spies T. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 2002;419:734-8.
33. Bauer S, Groh V, Wu J, et al. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 1999;285:727-9.
34. Li P, Morris DL, Willcox BE, et al. Complex structure of the activating immunoreceptor NKG2D, its MHC, class I-like ligand MICA. Nat Immunol 2001;2:443-51.
35. Groh V, Rhinehart R, Secrist H, et al. Broad tumor-associated expression and recognition by tumor-derived γδT cells of MICA and MICB. Proc Natl Acad Sci U S A 1999;96:6879-84.
36. Hayakawa Y, Kelly JM, Westwood JA, et al. Cutting edge: tumor rejection mediated by NKG2D receptor-ligand interaction is dependent upon perforin. J Immunol 2002;169:5377-81.
37. Patankar MS. Potent suppression of natural killer cell response mediated by the ovarian tumour marker CA125. Gynecol Oncol 2005;96:922.
38. Lum LG, Sen M. Activated T-cell and bispecific antibody immunotherapy for high-risk breast cancer. Bench to bedside. Acta Haematol 2001;105:130-6.
39. Werner M, Chott A, Fabiano A, Battifora H. Effect of formalin tissue fixation and processing on immunohistochemistry. Am J Surg Pathol 2000;24:1016-9.
40. Montera C. The antigen-antibody reaction in immunohistochemistry. J Histochem Cytochem 2003;51:1-4.
41. Epstein RJ. Preferential detection of catalytically inactive c-erbB-2 by antibodies to unphosphorylated peptides mimicking receptor tyrosine autophosphorylation sites. Oncogene 1995;11:315-23.
42. Fornier M, Seidman AD, Esteva FJ, et al. Weekly (W) Herceptin (H) + 1 hour Taxol (T): phase II study in HER2 overexpressing (H2+) and non-overexpressing (H2-) metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 1999;18:126a.